C3 rs2230199 (R102G) GG genotype increases complement activation and inflammatory risk.

The C3 rs2230199 (R102G) GG genotype is strongly associated with enhanced complement activation and an elevated risk of complement-mediated inflammation. This genetic variant, often referred to as the C3F (fast) allotype, alters the structure of the C3 protein, directly impacting the regulation and amplification of the complement system.

Mechanistic evidence

The rs2230199 polymorphism involves a substitution where arginine (R) is replaced by glycine (G) at position 102 in the MG1 domain of the C3 protein. This structural change has significant functional consequences:

• C3 Convertase Stability: The GG genotype facilitates faster assembly and increased stability of the alternative pathway (AP) C3 convertase (C3bBb). This leads to a potent positive feedback loop, amplifying the cleavage of C3 into active fragments C3a (a pro-inflammatory anaphylatoxin) and C3b.
• Biomarker Consumption: Increased activation throughput often results in the systemic consumption of native C3. Research in IgA nephropathy (IgAN) shows that the GG genotype correlates with lower plasma C3 levels alongside increased glomerular C3 deposits, indicating both systemic consumption and localized tissue inflammation.

Clinical/effectiveness evidence

The heightened activation associated with the GG genotype translates into a measurable increase in risk for several complement-driven pathologies:

• Age-Related Macular Degeneration (AMD): The G allele is a well-established risk factor for AMD, with odds ratios (OR) typically ranging from 1.4 to 2.3. AMD is characterized by chronic, complement-mediated inflammation within the ocular environment.
• Kidney Disease: In the context of chronic kidney disease, carriers of the G allele have shown a nearly threefold increase in risk for disease progression (HR 2.8) compared to those with the protective variant.
• Infectious and Systemic Stress: The GG genotype has been linked to a more than two-fold increased risk of severe malarial anemia (RR = 2.142), a condition driven by excessive complement-mediated clearance. Additionally, higher frequencies of the GG genotype have been observed in severe COVID-19 cases, suggesting a potential role in the hyper-inflammatory "cytokine storm."

Bottom line

The C3 rs2230199 GG genotype is a gain-of-function variant that increases alternative pathway activity by stabilizing C3 convertase. This results in greater complement-mediated inflammatory risk, particularly evident in conditions like AMD and progressive renal disease.